Axcella rises on launching mid-stage trial of liver disease treatment

Axcella Health

30/06/2021 13:09

** Biotech co's  AXLA.O  shares rise 2.9% to $4.15 premarket
    ** Co says it has activated initial clinical sites and
patient screening for mid-stage trial of its candidate, AXA1665,
for reducing risk of recurrent overt hepatic encephalopathy
 urn:newsml:reuters.com:*:nBw7mJcnba
    ** Overt hepatic encephalopathy is a common complication of
chronic liver disease and is characterized by several
neurological abnormalities
    ** Study will enroll about 150 patients who will be
randomized to receive either 53.8 grams per day of AXA1665 or
placebo in three doses for 24 weeks
    ** Stock down about 22% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))